Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

French pharma major Sanofi’s (Euronext: SAN) vaccines division, Sanofi Pasteur, has received approval from the US Food and Drug Administration for its supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine.

Fluzone Intradermal vaccine, which has been available in trivalent formulation for three years, is now available in a quadrivalent formulation to help protect against four strains of influenza virus. Fluzone Intradermal Quadrivalent vaccine is indicated for adults 18 through 64 years of age for active immunization for the prevention of influenza caused by influenza A subtype viruses and type B viruses contained in the vaccine.

"Influenza B is a common cause of influenza-related morbidity and mortality across all age groups," said David Greenberg, vice president, scientific and medical affairs, and chief medical officer, Sanofi Pasteur US. "Fluzone Intradermal Quadrivalent vaccine will offer another influenza vaccination option for health care providers and their adult patients with broad coverage against influenza viruses that may be predominant, coupled with the efficiency of using the intradermal microinjection system," he added.